Every 10-Q that Taysha Gene Therapies, Inc. (TSHA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TSHA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TSHA filings page.
Taysha Gene Therapies, Inc. reported no revenue for the three and six months ended June 30, 2026, compared with $1.99 million and $4.29 million in 2025 driven by prior Astellas collaboration revenue. Operating expenses rose sharply as the company advanced its gene therapy pipeline, with research and development reaching $38.6 million in the quarter and $72.4 million year-to-date, more than double the prior-year periods. Net loss widened to $46.6 million for the quarter and $89.0 million for the first half.
Taysha strengthened its balance sheet through a June 2026 underwritten offering of common stock and pre-funded warrants, generating $215.6 million in net proceeds at a public price of $6.00 per share. Cash and cash equivalents increased to $455.4 million as of June 30, 2026, from $319.8 million at year-end 2025, despite $81.3 million of operating cash outflows in the first half. The company also terminated its Durham manufacturing lease, recognizing a $3.4 million net gain and reducing long-term lease obligations.
Total assets were $470.4 million and total liabilities $83.2 million, including a Trinity term loan carried at fair value of $49.3 million and related success fee derivatives of $1.6 million. Stockholders’ equity increased to $387.3 million from $246.9 million at December 31, 2025, supported by equity financing. Management states that cash on hand is expected to fund planned operations for at least twelve months from issuance of these financial statements, but additional capital will be required to complete development and commercialization activities.
Taysha Gene Therapies reported a wider quarterly loss as it increased investment in gene therapy programs and collaboration revenue ended. For the three months ended March 31, 2026, revenue was $0 compared with $2.3 million a year earlier, when Astellas research revenue was recognized.
Research and development expense rose to $33.8 million from $15.6 million, and general and administrative expense increased to $9.7 million from $8.2 million, driving a net loss of $42.4 million versus $21.5 million. Operating cash outflow was $40.9 million. Cash and cash equivalents were $276.6 million, with total cash, cash equivalents and restricted cash of $279.3 million and total assets of $300.4 million. Management believes this cash will fund planned operations for at least twelve months. The company also carries a $50.0 million Trinity term loan measured at fair value and had an accumulated deficit of $753.7 million.
Taysha Gene Therapies reported Q3 2025 results showing higher liquidity and ongoing operating losses. Cash and cash equivalents were $297.3 million, up from $139.0 million at year-end, and total assets reached $316.6 million. The company recorded a Q3 net loss of $32.7 million (basic and diluted net loss per share $0.09) on operating expenses of $34.0 million, driven by research and development of $25.7 million and general and administrative of $8.3 million. Net cash used in operating activities for the first nine months was $66.4 million.
Liquidity improved through a May 2025 underwritten offering that generated $215.6 million in net proceeds and an August 2025 $50.0 million Tranche A term loan with Trinity; the 2023 Trinity loan was repaid at $40.6 million. Deferred revenue of $5.5 million tied to the Astellas Rett option is set to be recognized in Q4 2025 after the option expired unexercised, returning unencumbered rights to TSHA-102. As of November 4, 2025, common shares outstanding were 273,919,373.
Taysha Gene Therapies reported a strengthened balance sheet after a May 2025 underwritten offering that generated approximately $215.6 million in net proceeds, increasing cash and cash equivalents to $312.8 million and total assets to $333.3 million as of June 30, 2025. The company reported a net loss of $48.4 million for the six months ended June 30, 2025, which translates to a loss per share of $0.17 on a weighted-average share base of 283.7 million; research and development and general and administrative expenses totaled $52.5 million for the six-month period.
The company recognized $4.3 million of revenue related to Rett research and development activities in the six months, and deferred revenue related to the Astellas option totaled $5.5 million as of June 30, 2025. Taysha recorded the Trinity term loan at fair value and continues to mark the loan and a related success fee to market; the company stated it believes existing cash will be sufficient to fund planned operations for at least twelve months from issuance of these financial statements.